Multilocus genetic risk scores for venous thromboembolism risk assessment
Por:
Soria J.M., Morange P.-E., Vila J., Souto J.C., Moyano M., Trégouët D.-A., Mateo J., Saut N., Salas E., Elosua R.
Publicada:
1 ene 2014
Resumen:
Background-Genetics plays an important role in venous thromboembolism (VTE). Factor V Leiden (FVL or rs6025) and prothrombin gene G20210A (PT or rs1799963) are the genetic variants currently tested for VTE risk assessment. We hypothesized that primary VTE risk assessment can be improved by using genetic risk scores with more genetic markers than just FVL-rs6025 and prothrombin gene PT-rs1799963. To this end, we have designed a new genetic risk score called Thrombo inCode (TiC). Methods and Results-TiC was evaluated in terms of discrimination ( of the area under the receiver operating characteristic curve) and reclassification (integrated discrimination improvement and net reclassification improvement). This evaluation was performed using 2 age- and sex-matched case-control populations: SANTPAU (248 cases, 249 controls) and the Marseille Thrombosis Association study (MARTHA; 477 cases, 477 controls). TiC was compared with other literature-based genetic risk scores. TiC including F5 rs6025/rs118203906/rs118203905, F2 rs1799963, F12 rs1801020, F13 rs5985, SERPINC1 rs121909548, and SERPINA10 rs2232698 plus the A1 blood group (rs8176719, rs7853989, rs8176743, rs8176750) improved the area under the curve compared with a model based only on F5-rs6025 and F2-rs1799963 in SANTPAU (0.677 versus 0.575, P<0.001) and MARTHA (0.605 versus 0.576, P=0.008). TiC showed good integrated discrimination improvement of 5.49 (P<0.001) for SANTPAU and 0.96 (P=0.045) for MARTHA. Among the genetic risk scores evaluated, the proportion of VTE risk variance explained by TiC was the highest. Conclusions-We conclude that TiC greatly improves prediction of VTE risk compared with other genetic risk scores. TiC should improve prevention, diagnosis, and treatment of VTE. © 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Filiaciones:
Soria J.M.:
Unitat de Genòmica de Malalties Complexes, IIB-Sant Pau, Barcelona, Spain
Morange P.-E.:
Inserm UMR-S 1062, F-13385, Aix-Marseille Université, Marseille, France
Vila J.:
Grupo de Epidemiología y, Genética Cardiovascular, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain
CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain
Souto J.C.:
Unitat d'Hemostasia i Trombosis IIB-Sant Pau, Barcelona, Spain
Moyano M.:
Gendiag.exe, Barcelona, Spain
Trégouët D.-A.:
Inserm Unité Mixte de Recherche en Santé (UMR-S) 937, ICAN Institute for Cardiometabolism and Nutrition, Université Pierre et Marie Curie Paris 6, Paris, France
Mateo J.:
Unitat d'Hemostasia i Trombosis IIB-Sant Pau, Barcelona, Spain
Saut N.:
Inserm Unité Mixte de Recherche en Santé (UMR-S) 937, ICAN Institute for Cardiometabolism and Nutrition, Université Pierre et Marie Curie Paris 6, Paris, France
Salas E.:
Gendiag.exe, Barcelona, Spain
Elosua R.:
Grupo de Epidemiología y, Genética Cardiovascular, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain
Gold
|